The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.

Theseus Pharmaceuticals, a US-based targeted oncology drug developer backed by pharmaceutical firm Ariad Pharmaceuticals, has raised $160m in its initial public offering. The offering involved the sale of approximately 10 million shares on the Nasdaq Global Select Market priced at $16 apiece, at the top of the IPO’s $14 to $16 range. The share price…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.